Resminostat
Resminostat (pronounced as rez-min-o-stat) is a histone deacetylase inhibitor (HDAC inhibitor) that is primarily used in the treatment of cancer. It is an experimental drug that is currently under clinical trials.
Etymology
The term "Resminostat" is derived from the words "resistance" and "minostat". The "res" in Resminostat refers to the drug's ability to resist the growth of cancer cells, while "minostat" is a common suffix used in the names of HDAC inhibitors.
Pharmacology
Resminostat works by inhibiting the activity of histone deacetylases, a group of enzymes that remove acetyl groups from an ε-N-acetyl lysine amino acid on a histone. This allows the histones to wrap the DNA more tightly. By inhibiting these enzymes, Resminostat helps to stop the growth of cancer cells.
Clinical Trials
Resminostat has been tested in several clinical trials for its effectiveness in treating various types of cancer, including hepatocellular carcinoma, Hodgkin's lymphoma, and non-small cell lung cancer. The results of these trials have shown promise, but further research is needed to confirm the drug's effectiveness and safety.
Related Terms
- Histone deacetylase
- Histone deacetylase inhibitor
- Cancer
- Hepatocellular carcinoma
- Hodgkin's lymphoma
- Non-small cell lung cancer
External links
- Medical encyclopedia article on Resminostat
- Wikipedia's article - Resminostat
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski